BioNTech's second quarter revenue fell to €105.6 million on lower vaccine demand, prompting a cut to its full-year 2026 guidance.

BioNTech reported second quarter revenues of €105.6 million, a significant decline from the prior year, driven by lower demand for its COVID-19 vaccine. The company posted a diluted loss per share of €3.24 and subsequently revised its full-year 2026 revenue guidance downward.

Key Highlights

• Reported second quarter revenue of €105.6 million, down from €260.8 million in the prior-year period, due to softer global demand for COVID-19 vaccines.
• Recorded a diluted loss per share of €3.24, widening from a loss of €1.60 in the second quarter of 2025.
• Revised full-year 2026 revenue guidance to a range of €1.6 billion to €1.9 billion, down from the previous forecast of €2.0 billion to €2.3 billion.
• Reported second quarter adjusted R&D expenses of €477.1 million while advancing its oncology pipeline, which now includes 14 ongoing pivotal trials.